Last reviewed · How we verify

NCT01819818

A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients

Completed Last updated 27 April 2025
What this trial tests

trial testing No intervention in Schizophrenia in 3,267 participants. Completed in 29 November 2019.

Timeline
23 May 2011
Primary endpoint
29 November 2019
29 November 2019

Quick facts

Lead sponsorJanssen Korea, Ltd., Korea
StatusCompleted
Study typeOBSERVATIONAL
Enrollment3,267
Start date23 May 2011
Primary completion29 November 2019
Estimated completion29 November 2019
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Janssen Korea, Ltd., Korea — full company profile →

Who can join

Eligibility, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and tolerability of paliperidone palmitate over a 9-week period for participants with schizophrenia in Korea.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

Other Janssen Korea, Ltd., Korea trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01819818.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing